The 2013 ACC/AHA approach of starting a high-intensity statin and not treating to 2023 target LDL/apo B levels seemed to be the approach
D.ZhaoH.LiJ.TraganosF.StudzinskiG
Excretion of L-carnitine in man
Ideally, talk with both: Your NEN specialist or oncologist, and The clinician who prescribes your GLP-1 drug Ask how your specific tumor type and overall health fit into whats known so far, and whether there are alternative options if needed
Notably, researchers observed no similar reduction in hospitalizations unrelated to alcohol in T2D populations and smaller impacts on hospitalizations unrelated to alcohol in populations with obesity, suggesting the effect may be specific to alcohol-related outcomes, rather than confounding by underlying health status or general improvements in health
Considering the widespread expression of GLP-1 receptors in the brain, the authors recommend that future studies should focus on identifying the key neurocircuits involved in mediating the effects of GLP-1 receptor agonists on substance use disorder, as well as determine the specific patient subtypes who are most likely to benefit from these treatments
